All In Biotech

NDA 050810 · Thea Pharma

Azasite

Azithromycin · Ophthalmic

Last checked: Nov 19, 2026Latest source record: Jul 25, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Apr 27, 2007

Approved uses

1

Original approval plus efficacy supplements

Registered trials

627

181 Phase 3, 43 recruiting

FAERS reports

1,475

351 serious, 25 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 25, 2024.

AzaSite ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms: CDC coryneform group G Efficacy for this organism was studied in fewer than 10 infections. Haemophilus influenzae Staphylococcus aureus Streptococcus mitis group Streptococcus pneumoniae AzaSite is a macrolide antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms: CDC coryneform group G, Haemophilus influenzae, Staphylococcus aureus, Streptococcus mitis group, and Streptococcus pneumoniae. ( 1 )

Mechanism: Azithromycin is a macrolide antibiotic [see Clinical Pharmacology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • AZASITE · AZITHROMYCIN 1% · SOLUTION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Azithromycin" as an intervention, any sponsor and status, largest first.

All 627 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • no adverse event421
  • drug dose omission329
  • product quality issue276
  • inappropriate schedule of drug administration211
  • eye irritation195
  • product packaging quantity issue146
  • off label use143
  • drug ineffective132
  • eye pain105
  • eye pruritus105
  • dyspnoea102
  • lacrimation increased91

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20073
200816
200912
201014
201115
2012201
2013481
201443
201534
201664
201736
201839
201972
2020118
202173
202265
202367
202439
202538
202645

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Azasite (Azithromycin)

2024 spending

$1.6M

Beneficiaries

3,244

5,084 claims

Per beneficiary

$485

$99.61 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$1,296,942
2024$1,574,632

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,832 on PubMed

Sponsor: Thea Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.